Hims & Hers Health (NYSE:HIMS) fell ~19% in the premarket on Tuesday, even as the telehealth company reported better-than-expected Q4 2024 financials and set its 2025 outlook above consensus during ...
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...
Apple’s latest $500 billion pledge could soften tariff blow, Robinhood is latest to see SEC abandon its crypto case, and more ...
Hims & Hers Health shares tumbled despite the telehealth provider beating fourth-quarter expectations and offering ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS – Research Report) and Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback